D.E. Shaw & Co
CERO

D.E. Shaw & Co’s CERo Therapeutics CERO Stock Holding History

D.E. Shaw & Co’s Portfolio CERO Stock Details CERO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q4 		– Sell
-374
Closed -$7.55M – 5181
2022
Q3 		$7.55M Buy
374
+6
+2% +$121K 0.01% 1625
2022
Q2 		$7.37M Buy
368
+63
+21% +$1.26M 0.01% 1699
2022
Q1 		$6.1M Buy
305
+67
+28% +$1.33M 0.01% 2088
2021
Q4 		$4.72M Buy
+238
New +$4.72M ﹤0.01% 2435

Other funds holding CERO

SCM
Saba Capital Management New York $3.62B AUM 13% 1-Year Est. Return
HSBC Holdings
HSBC Holdings London, United Kingdom $192B AUM 27.2% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
WCMNY
Westchester Capital Management (New York) Valhalla, New York $2.21B AUM 26.02% 1-Year Est. Return
PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return
PC
Periscope Capital Toronto, Ontario, Canada $902M AUM 6.51% 1-Year Est. Return
BCM
Beryl Capital Management Redondo Beach, California $110M AUM 317.92% 1-Year Est. Return
HIM
HGC Investment Management Toronto, Ontario, Canada $451M AUM 8.78% 1-Year Est. Return
FTCM
First Trust Capital Management Chicago, Illinois $1.9B AUM 58.39% 1-Year Est. Return
WRBC
W.R. Berkley Corp Greenwich, Connecticut $1.86B AUM 14.44% 1-Year Est. Return

D.E. Shaw & Co's CERO Position: Q4 2022 in Review

D.E. Shaw & Co sold out of CERo Therapeutics (CERO) in Q4 2022, closing a stake of 374 shares — an estimated $7.55M sold.

D.E. Shaw & Co first reported a position in CERO in Q4 2021 and held it in 4 quarters. The position peaked at $7.55M in Q3 2022. 45 funds tracked by Wall St. Rank hold CERO as of Q4 2022.

  • D.E. Shaw & Co reported no remaining CERo Therapeutics position as of Q4 2022 after selling out during the quarter.
  • D.E. Shaw & Co sold 374 CERo Therapeutics shares in Q4 2022, an estimated $7.55M.
  • D.E. Shaw & Co first reported a position in CERo Therapeutics in Q4 2021 and held it in 4 quarters.
  • D.E. Shaw & Co's CERo Therapeutics position peaked at $7.55M in Q3 2022.
  • 45 funds tracked by Wall St. Rank held CERo Therapeutics as of Q4 2022.

Based on D.E. Shaw & Co's 13F filing for Q4 2022, filed 14 Feb 2023.